145 related articles for article (PubMed ID: 33794385)
1. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
[TBL] [Abstract][Full Text] [Related]
2. From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).
Klövekorn P; Pfaffenrot B; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jan; 210():112963. PubMed ID: 33199152
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.
Kircher T; Pantsar T; Oder A; Peter von Kries J; Juchum M; Pfaffenrot B; Kloevekorn P; Albrecht W; Selig R; Laufer S
Eur J Med Chem; 2021 Jan; 209():112901. PubMed ID: 33092905
[TBL] [Abstract][Full Text] [Related]
5. Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.
Juchum M; Pfaffenrot B; Klövekorn P; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2022 Oct; 240():114584. PubMed ID: 35868124
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.
Qiao L; Choi S; Case A; Gainer TG; Seyb K; Glicksman MA; Lo DC; Stein RL; Cuny GD
Bioorg Med Chem Lett; 2009 Nov; 19(21):6122-6. PubMed ID: 19783434
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel pyrazolo[1,5-a]pyridine-based EP
Nishigaya Y; Umei K; Saito Y; Watanabe H; Kondo T; Kondo A; Kawamura N; Tatani K; Kohno Y; Tanaka N; Seto S
Bioorg Med Chem Lett; 2017 Sep; 27(17):4044-4050. PubMed ID: 28784294
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors.
Stevens KL; Jung DK; Alberti MJ; Badiang JG; Peckham GE; Veal JM; Cheung M; Harris PA; Chamberlain SD; Peel MR
Org Lett; 2005 Oct; 7(21):4753-6. PubMed ID: 16209527
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors.
Yang B; Wu Q; Huan X; Wang Y; Sun Y; Yang Y; Liu T; Wang X; Chen L; Xiong B; Zhao D; Miao Z; Chen D
Bioorg Med Chem Lett; 2021 Feb; 33():127749. PubMed ID: 33340663
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
